Grants and Contributions

The outcome will validate SyncMed’s capacity to support real-time clinical handovers with AI-driven documentation tools.

The firm is targeting early adopter customers who value modernized treatment solutions, prefer Western/European medical devices, and are open to piloting the firm's products in clinical settings. Vietnam (Hanoi) is the firm's first choice due to strong ties with the national hospital network, their familiarity with oncology QA devices, and growing demand for advanced patient positioning.

The use of automated prognostic imaging biomarkers in clinical practice may enhance (re-) staging and response assessment, as it could inform more personalized treatment selection and patient monitoring, which in turn could lead to improved patient outcomes.

In-house capability to produce two integrated microfluidic discs (Clinical Chemistry, Immunoassay) that meet required specifications and reproducibility.

Pre-clinical proof-of-concept studies to assess therapeutic activity in an mRNA-LNP Delivered SMYD3 Peptide Therapeutic both patient-derived cell lines and a murine xenograft model of SCLC.

This project aims to advance the Firm's metabolomics profiling system into a scalable, high-throughput platform for clinical and precision health applications. Building on foundational work completed in the first year, the focus now shifts to upgrading lab methods and bioinformatics tools to support the processing of over 300 samples per day, validating the system with large-scale cohorts (~30,000 samples), and developing a prototype precision health platform that integrates analytics, a database, and AI-driven health assessment tools.

With GAC’s support, the Union of Medical Care and Relief Organizations – International (UOSSM) will aim to increase access to primary healthcare services through mobile clinics and strengthened referral networks, increase screening and treatment of moderate and severe acute malnutrition among children under five, and increase access to mental health and psychosocial support (MHPSS), including for survivors of Gender Based Violence (GBV).

Through agile collaboration with veterinarians, the team gathers clinical requirements, coordinates structured interviews, and manages data acquisition and labelling.

Development of evidence-based health algorithms.

Then, SPA2 will measure hemolysis and hemolysis markers using comprehensive clinical and laboratory techniques.